Xencor

Historical price data

Xencor is a publicly traded biotechnology company focused on redesigning antibody drugs from the ground up using its core XmAb Fc domain engineering platform. The company has established a robust pipeline of over 20 clinical-stage programs and has successfully partnered its technology, resulting in three marketed drugs. Xencor's strategy combines proprietary drug development in oncology and autoimmunity with a prolific licensing model that extends its technology to major pharmaceutical partners.

XmAb® protein engineering platform that uses rational design to modify antibody Fc domains, enabling enhanced functions like extended half-life, increased cytotoxicity, and stable bispecific antibody structures in a 'plug-and-play' format.

25 drugs in pipeline

Total raised: $82M

Xencor competes with large biopharma and specialized biotechs in antibody engineering (e.g., Regeneron, Adimab) and bispecific development (e.g., Amgen, Roche). Its differentiation stems from its modular, Fc-focused 'plug-and-play' platform, which offers partners and internal programs a streamlined path to improved antibody performance and novel bispecific formats.